Two Sigma Advisers
PRVL

Two Sigma Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Two Sigma Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,200
Closed -$420K – 2801
2020
Q4 		$420K Sell
18,200
-11,700
-39% -$148K ﹤0.01% 1932
2020
Q3 		$304K Buy
+29,900
New +$401K ﹤0.01% 2006

Two Sigma Advisers's PRVL Position: Q1 2021 in Review

Two Sigma Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 18,200 shares — an estimated $420K sold.

Two Sigma Advisers first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $420K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Two Sigma Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 18,200 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $420K.
  • Two Sigma Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Two Sigma Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $420K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Two Sigma Advisers's 13F filing for Q1 2021, filed 17 May 2021.